• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Viramune (nevirapine) Tablets, Oral Suspension and Virammune XR Extended-Release Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2011

 

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • decreased serum phosphorus